dacarbazine and bibw 2992

dacarbazine has been researched along with bibw 2992 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S	1
Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F	1
Bender, S; Brada, M; Cseh, A; Gattamaneni, R; Harris, F; James, A; Jefferies, S; McBain, C; Pemberton, K; Saran, F; Schaible, J; Welsh, L	1

Trials

2 trial(s) available for dacarbazine and bibw 2992

Article	Year
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-oncology, 2015, Volume: 17, Issue:3 Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome	2015
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. Journal of neuro-oncology, 2021, Volume: 155, Issue:3 Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome	2021

Article

Year

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Neuro-oncology, 2015, Volume: 17, Issue:3

Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome

2015

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.

Journal of neuro-oncology, 2021, Volume: 155, Issue:3

Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome

2021

Other Studies

1 other study(ies) available for dacarbazine and bibw 2992

Article	Year
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome	2015

Article

Year

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

Oncotarget, 2015, Oct-20, Volume: 6, Issue:32

Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome

2015